Agreements reached under this partnership
Business Alliances- 1
SANTEN PHARMACEUTICAL CO.,LTD. will continue to be responsible for manufacturing and marketing the product and promoting it in the ophthalmology field.
- 2
杏林製薬 plans to begin promoting the product to medical institutions outside the ophthalmology field around August 2026.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The Company will promptly announce any information that becomes necessary regarding the impact of this matter on its consolidated earnings forecasts for the fiscal year ending March 2027.
| Item | Details |
|---|---|
| Name of alliance partner | SANTEN PHARMACEUTICAL CO.,LTD. |
| Alliance partner's business activities | A global pharmaceutical company specializing in ophthalmology. It conducts research and development, manufacturing, and sales of pharmaceuticals and medical devices in the ophthalmology field, and has a product portfolio covering a broad range of disease areas, including glaucoma, dry eye, infectious diseases, allergies, age-related macular degeneration, and myopia. |
| Alliance partner's location | Osaka City, Osaka Prefecture |
| Type of alliance | Business Alliances |
| Details of the alliance | SANTEN PHARMACEUTICAL CO.,LTD. will continue to be responsible for manufacturing and marketing the product and promoting it in the ophthalmology field., 杏林製薬 plans to begin promoting the product to medical institutions outside the ophthalmology field around August 2026. |
| Contract Date | 13 July 2026 |
| Alliance start date | 杏林製薬 plans to begin promoting the product to medical institutions outside the ophthalmology field around August 2026. |
| Impact on Business Performance | The Company will promptly announce any information that becomes necessary regarding the impact of this matter on its consolidated earnings forecasts for the fiscal year ending March 2027. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The agreement combines 杏林製薬’s expertise in allergic diseases and its sales and marketing platform in the respiratory and otolaryngology fields with SANTEN PHARMACEUTICAL CO.,LTD.’s specialized expertise in ophthalmology, with the aim of making Alesion Eyelid Cream available to more patients and contributing to improvements in patients’ quality of life.